Your browser doesn't support javascript.
loading
APRIL:TACI axis is dispensable for the immune response to rabies vaccination.
Haley, Shannon L; Tzvetkov, Evgeni P; Lytle, Andrew G; Alugupalli, Kishore R; Plummer, Joseph R; McGettigan, James P.
Afiliação
  • Haley SL; Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Tzvetkov EP; Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Lytle AG; Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Alugupalli KR; Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Plummer JR; Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States.
  • McGettigan JP; Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States; Jefferson Vaccine Center, Thomas Jefferson University, Philadelphia, PA, United States. Electronic address: James.McGettigan@jefferson.edu.
Antiviral Res ; 144: 130-137, 2017 08.
Article em En | MEDLINE | ID: mdl-28619678
ABSTRACT
There is significant need to develop a single-dose rabies vaccine to replace the current multi-dose rabies vaccine regimen and eliminate the requirement for rabies immune globulin in post-exposure settings. To accomplish this goal, rabies virus (RABV)-based vaccines must rapidly activate B cells to secrete antibodies which neutralize pathogenic RABV before it enters the CNS. Increased understanding of how B cells effectively respond to RABV-based vaccines may improve efforts to simplify post-exposure prophylaxis (PEP) regimens. Several studies have successfully employed the TNF family cytokine a proliferation-inducing ligand (APRIL) as a vaccine adjuvant. APRIL binds to the receptors TACI and B cell maturation antigen (BCMA)-expressed by B cells in various stages of maturation-with high affinity. We discovered that RABV-infected primary murine B cells upregulate APRIL ex vivo. Cytokines present at the time of antigen exposure affect the outcome of vaccination by influencing T and B cell activation and GC formation. Therefore, we hypothesized that the presence of APRIL at the time of RABV-based vaccine antigen exposure would support the generation of protective antibodies against RABV glycoprotein (G). In an effort to improve the response to RABV vaccination, we constructed and characterized a live recombinant RABV-based vaccine vector which expresses murine APRIL (rRABV-APRIL). Immunogenicity testing in mice demonstrated that expressing APRIL from the RABV genome does not impact the primary antibody response against RABV G compared to RABV alone. In order to evaluate the necessity of APRIL for the response to rabies vaccination, we compared the responses of APRIL-deficient and wild-type mice to immunization with rRABV. APRIL deficiency does not affect the primary antibody response to vaccination. Furthermore, APRIL expression by the vaccine did not improve the generation of long-lived antibody-secreting plasma cells (PCs) as serum antibody levels were equivalent in response to rRABV-APRIL and the vector eight weeks after immunization. Moreover, APRIL is dispensable for the long-lived antibody-secreting PC response to rRABV vaccination as anti-RABV G IgG levels were similar in APRIL-deficient and wild-type mice six months after vaccination. Mice lacking the APRIL receptor TACI demonstrated primary anti-RABV G antibody responses similar to wild-type mice following immunization with the vaccine vector indicating that this response is independent of TACI-mediated signals. Collectively, our findings demonstrate that APRIL and associated TACI signaling is dispensable for the immune response to RABV-based vaccination.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina Antirrábica / Adjuvantes Imunológicos / Membro 13 da Superfamília de Ligantes de Fatores de Necrose Tumoral / Proteína Transmembrana Ativadora e Interagente do CAML Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina Antirrábica / Adjuvantes Imunológicos / Membro 13 da Superfamília de Ligantes de Fatores de Necrose Tumoral / Proteína Transmembrana Ativadora e Interagente do CAML Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article